annual EBITDA:
$9.11B+$410.22M(+4.71%)Summary
- As of today (September 17, 2025), TAK annual EBITDA is $9.11 billion, with the most recent change of +$410.22 million (+4.71%) on March 1, 2025.
- During the last 3 years, TAK annual EBITDA has fallen by -$1.51 billion (-14.23%).
- TAK annual EBITDA is now -14.23% below its all-time high of $10.62 billion, reached on March 31, 2022.
Performance
TAK EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
$2.58B+$1.13B(+78.27%)Summary
- As of today (September 17, 2025), TAK quarterly EBITDA is $2.58 billion, with the most recent change of +$1.13 billion (+78.27%) on June 1, 2025.
- Over the past year, TAK quarterly EBITDA has dropped by -$67.34 million (-2.55%).
- TAK quarterly EBITDA is now -30.61% below its all-time high of $3.71 billion, reached on June 30, 2021.
Performance
TAK quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$8.84B-$67.34M(-0.76%)Summary
- As of today (September 17, 2025), TAK TTM EBITDA is $8.84 billion, with the most recent change of -$67.34 million (-0.76%) on June 1, 2025.
- Over the past year, TAK TTM EBITDA has increased by +$540.69 million (+6.51%).
- TAK TTM EBITDA is now -16.87% below its all-time high of $10.64 billion, reached on September 30, 2021.
Performance
TAK TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TAK EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +4.7% | -2.5% | +6.5% |
| 3 y3 years | -14.2% | +0.9% | -3.9% |
| 5 y5 years | +11.8% | -5.1% | +0.7% |
TAK EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -14.2% | +4.7% | -3.9% | +78.3% | -7.1% | +6.5% |
| 5 y | 5-year | -14.2% | +11.8% | -30.6% | +78.3% | -16.9% | +6.5% |
| alltime | all time | -14.2% | +1491.7% | -30.6% | +234.8% | -16.9% | >+9999.0% |
TAK EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $2.58B(+78.3%) | $8.84B(-0.8%) |
| Mar 2025 | $9.11B(+4.7%) | $1.45B(-34.9%) | $8.91B(-1.9%) |
| Dec 2024 | - | $2.22B(-14.5%) | $9.08B(-0.0%) |
| Sep 2024 | - | $2.60B(-1.7%) | $9.08B(+9.4%) |
| Jun 2024 | - | $2.64B(+63.4%) | $8.30B(-0.4%) |
| Mar 2024 | $8.70B(-10.9%) | $1.62B(-27.2%) | $8.34B(-3.9%) |
| Dec 2023 | - | $2.22B(+22.4%) | $8.68B(-3.9%) |
| Sep 2023 | - | $1.82B(-32.2%) | $9.03B(-5.2%) |
| Jun 2023 | - | $2.68B(+37.1%) | $9.52B(+1.4%) |
| Mar 2023 | $9.76B(-8.1%) | $1.95B(-24.0%) | $9.39B(+2.5%) |
| Dec 2022 | - | $2.57B(+11.4%) | $9.16B(+0.3%) |
| Sep 2022 | - | $2.31B(-9.6%) | $9.14B(-0.7%) |
| Jun 2022 | - | $2.55B(+47.9%) | $9.20B(-11.2%) |
| Mar 2022 | $10.62B(+11.8%) | $1.73B(-32.2%) | $10.36B(-1.0%) |
| Dec 2021 | - | $2.55B(+7.1%) | $10.47B(-1.6%) |
| Sep 2021 | - | $2.38B(-35.9%) | $10.64B(+1.1%) |
| Jun 2021 | - | $3.71B(+102.8%) | $10.52B(+10.5%) |
| Mar 2021 | $9.50B(+16.5%) | $1.83B(-32.6%) | $9.52B(-1.4%) |
| Dec 2020 | - | $2.71B(+20.1%) | $9.66B(+10.0%) |
| Sep 2020 | - | $2.26B(-16.7%) | $8.78B(-0.1%) |
| Jun 2020 | - | $2.71B(+37.9%) | $8.79B(+7.6%) |
| Mar 2020 | $8.15B(+93.8%) | $1.97B(+7.3%) | $8.16B(+21.4%) |
| Dec 2019 | - | $1.84B(-19.0%) | $6.72B(+10.2%) |
| Sep 2019 | - | $2.27B(+8.4%) | $6.10B(+28.2%) |
| Jun 2019 | - | $2.09B(+296.1%) | $4.76B(+22.9%) |
| Mar 2019 | $4.21B(+23.5%) | $528.10M(-56.5%) | $3.87B(+3.2%) |
| Dec 2018 | - | $1.21B(+31.1%) | $3.75B(+5.8%) |
| Sep 2018 | - | $925.04M(-23.1%) | $3.54B(+2.2%) |
| Jun 2018 | - | $1.20B(+195.4%) | $3.47B(+3.9%) |
| Mar 2018 | $3.41B(+42.7%) | $407.46M(-59.5%) | $3.34B(+3.3%) |
| Dec 2017 | - | $1.01B(+18.4%) | $3.23B(-0.5%) |
| Sep 2017 | - | $849.81M(-20.9%) | $3.25B(+5.6%) |
| Jun 2017 | - | $1.07B(+255.2%) | $3.08B(+7.6%) |
| Mar 2017 | $2.39B(-18.9%) | $302.29M(-70.4%) | $2.86B(+0.3%) |
| Dec 2016 | - | $1.02B(+51.2%) | $2.85B(+4.3%) |
| Sep 2016 | - | $676.65M(-21.0%) | $2.73B(-6.5%) |
| Jun 2016 | - | $856.17M(+191.7%) | $2.92B(+1.7%) |
| Mar 2016 | $2.94B(-16.6%) | $293.54M(-67.6%) | $2.87B(+330.1%) |
| Dec 2015 | - | $904.99M(+4.6%) | $667.73M(-13.2%) |
| Sep 2015 | - | $865.52M(+7.2%) | $769.06M(+2.1%) |
| Jun 2015 | - | $807.67M(-142.3%) | $753.57M(-5.9%) |
| Mar 2015 | $3.53B | -$1.91B(-289.8%) | $800.88M(-70.5%) |
| Dec 2014 | - | $1.01B(+18.4%) | $2.71B(-8.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2014 | - | $850.03M(-0.6%) | $2.95B(-7.3%) |
| Jun 2014 | - | $854.98M(-31.5%) | $3.18B(-12.6%) |
| Mar 2014 | $3.32B(+10.1%) | - | - |
| Dec 2013 | - | $1.25B(+15.4%) | $3.64B(+3.4%) |
| Sep 2013 | - | $1.08B(+5.7%) | $3.53B(-3.7%) |
| Jun 2013 | - | $1.02B(+249.8%) | $3.66B(-8.6%) |
| Mar 2013 | $3.02B(-42.6%) | $292.55M(-74.1%) | $4.00B(-6.7%) |
| Dec 2012 | - | $1.13B(-7.2%) | $4.29B(-4.1%) |
| Sep 2012 | - | $1.22B(-11.0%) | $4.48B(-7.6%) |
| Jun 2012 | - | $1.37B(+135.0%) | $4.85B(-7.7%) |
| Mar 2012 | $5.26B(-5.0%) | $581.52M(-55.7%) | $5.25B(-3.8%) |
| Dec 2011 | - | $1.31B(-17.3%) | $5.46B(-6.0%) |
| Sep 2011 | - | $1.59B(-10.3%) | $5.81B(-1.1%) |
| Jun 2011 | - | $1.77B(+123.6%) | $5.87B(+5.5%) |
| Mar 2011 | $5.53B(-4.0%) | $791.44M(-52.4%) | $5.56B(-3.6%) |
| Dec 2010 | - | $1.66B(+0.8%) | $5.77B(+1.5%) |
| Sep 2010 | - | $1.65B(+12.9%) | $5.69B(+1.5%) |
| Jun 2010 | - | $1.46B(+46.0%) | $5.61B(-2.4%) |
| Mar 2010 | $5.76B(+36.5%) | $1.00B(-36.6%) | $5.75B(-0.7%) |
| Dec 2009 | - | $1.58B(+0.7%) | $5.79B(-5.8%) |
| Sep 2009 | - | $1.57B(-2.2%) | $6.14B(+3.6%) |
| Jun 2009 | - | $1.60B(+53.9%) | $5.93B(+38.3%) |
| Mar 2009 | $4.22B(+6.1%) | $1.04B(-46.1%) | $4.29B(+32.1%) |
| Dec 2008 | - | $1.93B(+42.9%) | $3.25B(+147.1%) |
| Sep 2008 | - | $1.35B(-3585.3%) | $1.31B(-3485.3%) |
| Jun 2008 | - | -$38.80M | -$38.80M |
| Mar 2008 | $3.98B(-4.5%) | - | - |
| Mar 2007 | $4.17B(+9.3%) | - | - |
| Mar 2006 | $3.81B(-1.6%) | - | - |
| Mar 2005 | $3.87B(+9.5%) | - | - |
| Mar 2004 | $3.54B(+26.6%) | - | - |
| Mar 2003 | $2.79B(+12.8%) | - | - |
| Mar 2002 | $2.48B(+5.5%) | - | - |
| Mar 2001 | $2.35B(+27.7%) | - | - |
| Mar 2000 | $1.84B(+33.6%) | - | - |
| Mar 1999 | $1.38B(+16.1%) | - | - |
| Mar 1998 | $1.19B(-15.7%) | - | - |
| Mar 1997 | $1.41B(-7.1%) | - | - |
| Mar 1996 | $1.51B(+19.1%) | - | - |
| Mar 1995 | $1.27B(+71.1%) | - | - |
| Mar 1994 | $743.36M(+29.9%) | - | - |
| Mar 1993 | $572.38M(-19.4%) | - | - |
| Mar 1992 | $709.98M(+22.1%) | - | - |
| Mar 1991 | $581.40M | - | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual EBITDA?
- What is the all time high annual EBITDA for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual EBITDA year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly EBITDA?
- What is the all time high quarterly EBITDA for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly EBITDA year-on-year change?
- What is Takeda Pharmaceutical Company Limited TTM EBITDA?
- What is the all time high TTM EBITDA for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited TTM EBITDA year-on-year change?
What is Takeda Pharmaceutical Company Limited annual EBITDA?
The current annual EBITDA of TAK is $9.11B
What is the all time high annual EBITDA for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual EBITDA is $10.62B
What is Takeda Pharmaceutical Company Limited annual EBITDA year-on-year change?
Over the past year, TAK annual EBITDA has changed by +$410.22M (+4.71%)
What is Takeda Pharmaceutical Company Limited quarterly EBITDA?
The current quarterly EBITDA of TAK is $2.58B
What is the all time high quarterly EBITDA for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly EBITDA is $3.71B
What is Takeda Pharmaceutical Company Limited quarterly EBITDA year-on-year change?
Over the past year, TAK quarterly EBITDA has changed by -$67.34M (-2.55%)
What is Takeda Pharmaceutical Company Limited TTM EBITDA?
The current TTM EBITDA of TAK is $8.84B
What is the all time high TTM EBITDA for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high TTM EBITDA is $10.64B
What is Takeda Pharmaceutical Company Limited TTM EBITDA year-on-year change?
Over the past year, TAK TTM EBITDA has changed by +$540.69M (+6.51%)